Redx Pharma Limited - Redx Pharma to present new Phase 2a data at ERS

REDX PHARMA LIMITED

("Redx" or the "Company")

Redx to present new data for zelasudil (RXC007) for the treatment of Idiopathic Pulmonary Fibrosis at ERS

The oral presentation "Phase 2a signal searching study with zelasudil in idiopathic pulmonary fibrosis (IPF)" will be presented on Sunday 28 September

Alderley Park, UK,  22 September  2025 Redx Pharma, the clinical-stage biotechnology company focused on developing novel, small molecule, targeted therapeutics for fibrotic disease, will present new data from the zelasudil Phase 2a signal searching study in idiopathic pulmonary fibrosis (IPF) at the European Respiratory Society (ERS) meeting in Amsterdam. The oral presentation will be given by Professor Toby Maher, zelasudil Phase 2 Chief Investigator and Professor of Clinical Medicine and Director of the Interstitial Lung Disease Programme at Keck School of Medicine at the University of Southern California.

Zelasudil is a potent, oral, small molecule, selective, Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor. The Phase 2a study assessed safety, tolerability, pharmacokinetic and initial efficacy in patients with IPF.

IPF is a debilitating disease of the lungs which progressively causes scarring and a reduction in lung function. Occurring primarily in older adults (>50 years old), it involves irreversible and variable scarring, stiffening, and thickening of the lung tissues, leading to patients experiencing shortness of breath and lack of oxygen absorption. Over 170,000 patients suffer with IPF[i] and around a further 53,000 people are diagnosed each year (US, 5 EU, Japan). Patients diagnosed with IPF have an estimated life expectancy of 3 to 5 years[ii]. There is no known cure and current treatment only slows progression of the disease.

About Redx Pharma Limited

Redx Pharma is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicine for the treatment of fibrotic disease. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry-leading ROCK inhibitor portfolio through the clinic, comprising of zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, and RXC008, a GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry, translational science and clinical development, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which include the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor, now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.